23 patients with ALL (n ¼ 9) and AML (n ¼ 14) underwent nonmyeloablative stem cell transplantation (NST) from an HLA-identical donor after conditioning with fludarabine (180 mg/m 2
Nonmyeloablative stem cell transplantation (NST) can be performed in patients with haematologic diseases, who are considered ineligible for standard high-dose chemotherapy and total-body-irradiation (TBI) because of age, intensive pretreatment, compromised organ function or active infections. Successful engraftment after dose-reduced conditioning is based on sufficient immunosuppression rather than on the cytotoxic effect of high-dose therapy.
1,2 Engraftment of allogeneic progenitor cells is a predictor of survival 3 and a prerequisite for the induction of a graft-versus-leukaemia (GvL)-effect.
NST can lead to stable engraftment, induce mixed chimerism (MC) or complete donor chimerism (CC) and complete remissions (CR). [4] [5] [6] [7] [8] However, the rate of engraftment failure reported was substantial in some studies, and optimal conditioning regimen as well as post-transplant immunosuppression is under investigation. 8, 9 Quantitative analysis of leucocyte subsets by multiplex PCR using short tandem repeat (STR) markers and fluorescence detection system has been a useful tool for the assessment of chimeric states even with very low numbers of cells and in the absence of molecular markers. 10, 11 The prognostic significance of MC has only partially been elucidated so far. Canine studies have demonstrated stable MC after sublethal irradiation and postgrafting immunosuppression with cyclosporine A (CSA) and mycophenolate mofetil (MMF). 12 However, a higher risk of relapse has been reported in patients with sustained MC after allogeneic stem cell transplantation (SCT). 13, 14 Data on the efficacy of NST in high-risk AML and ALL, and the role of MC in these patients are still scarce and inconclusive. 7, 15 Patients with relapsing acute leukaemias after allogeneic SCT have a poor prognosis and donor lymphocyte infusions (DLIs) have had only very limited effect in patients with AML and virtually none in ALL in contrast to patients with CML. [16] [17] [18] A prevention of relapse in acute leukaemias by early DLI seems to be possible in some patients. 19 We report on 23 adult patients with high-risk acute leukaemias after dose-reduced conditioning and prophylactic application of DLI in order to prevent relapse.
Patients and methods

Patients
In all, 23 patients with high-risk acute leukaemias underwent NST from HLA-identical donors between October 1998 and October 2001 (Table 1) . 14 of 23 patients (61%), had uncontrolled disease. Time from diagnosis to NST was 8.2 months in median (range 3.3-35 months).
Contraindications against standard high-dose conditioning regimens were age above 50 years (n ¼ 6), intensive pretreatment with mediastinal or total lymph node irradiation (n ¼ 2), relapse after standard SCT (n ¼ 6), and infections (n ¼ 9). Salvage NST after failure of standard SCT was performed from the same donor in 5/6 and from a second donor in 1/6 patients.
Conditioning therapy consisted of fludarabine 30 mg/m 2 i.v. daily on day À10 till day À5 (total dose 180 mg/m 2 ), busulfan 4 mg/kg p.o. daily on day À6 and day À5 (total dose 8 mg/kg) and anti-T lymphocyte globulin (ATG) 10 mg/kg i.v. daily on day À4 till day À1 (total dose 40 mg/ kg), 1/23 patients received no ATG. 4 Patients were transplanted with a median of 4.0 Â 10 6 CD34+ cells/kg body weight (range 2.1-19.8). Graft versus-host disease (GvHD)-prophylaxis was performed with CSA alone (2.5 mg/kg twice daily i.v.) starting at day À1 and tapering after day +60 except one patient who received CSA and MMF 2 Â 1 g/day ( 
Chimerism analysis
Chimerism analysis from peripheral blood was started after haematopoietic reconstitution at day 28 and then at 2 to 4-week intervals for 1 year at least. Bone marrow samples were analysed 2 weeks, 1, 3, 6, and 12 months after NST at least.
MC was defined as 5% or more recipient cells in at least one leucocyte subpopulation-specific analysis in two independent analyses after haematopoietic reconstitution.
Sample preparation
Blood samples were collected from donor and recipient before transplant.
Approximately 10 ml peripheral EDTA-blood was sorted with antibody-coated Dynabeads (Deutsche Dynal GmbH, Hamburg, Germany) against CD4, CD8, CD3, CD19, CD14, CD15 and CD2; bone marrow was analysed with antibodies against CD34. Residual cells were also analysed. The purity of the specific lineages was controlled by FACS analysis after detaching the beads at different stages (Becton Dickinson, Heidelberg, Germany), and was determined to be more than 93%.
DNA extraction and STR analysis
Genomic DNA was extracted from sorted blood and marrow samples using standard procedures. 20 DNA was also prepared using silica membranes (Qiamp Blood Kit, Qiagen, Hilden, Germany). Prior to STR amplification, all DNA samples were quantitated and diluted to optimal working concentrations.
STR polymorphisms were analysed on ABI PRISM 310 Genetic Analyzer (PE Applied Biosystems, Darmstadt, Germany) after coamplification of nine STRs D3S1358/ vWA/FGA, D8S1179/D21S11/D18S51 and D5S818/ D13S317/D7S820 plus the Amelogenin gene [21] [22] [23] [24] [25] [26] [27] with the AmpFlSTR Profilerplus Kit (PE Applied Biosystems, Darmstadt, Germany).
We determined the ratio of donor and recipient by calculating the proportion of the peak areas of donor and recipient signals. 10 The estimated detection limit for the AmpFlSTR Profilerplus multiplex system is about 5% for the minor component in a mixed sample. A minimum total number of 1000 cells have been regarded as sufficient for conclusive analysis. 28 Samples were excluded from the analysis, when no unequivocal donor or recipient profile was detected.
Results
Of 23 patients, 20 (87%) engrafted after NST. Two of 23 reconstituted with leukaemia. One of 23 had a graft failure and was successfully retransplanted after standard highdose conditioning. Ten of 14 patients (71%) with active disease reached CR after NST. After a median follow-up of 9 months (range 2-34 months), 10/23 patients are alive (43%), 9/10 are in CR. Three surviving patients in CR had uncontrolled disease before NST. In total, 12 patients have died from relapsing or refractory leukaemia 2-22 months after NST (6 months in median). One patient has died 3 months after NST from sepsis and acute GvHD grade III after DLI. All patients who received salvage NST have died from leukaemia. The probability of overall survival is 48% after 12 months and 35% after 24 months (Figure 1 ).
High precision of chimerism analysis
STR analysis revealed informative recipient and donorspecific profiles in all patients.
No unequivocal donor or recipient profile was detected in 3.5% (37 of 1059 analyses) of the cell-type-specific STR analyses very early after transplantation, because the minimum number of cells required could not be separated at that time.
Frequent encounter of mixed chimerism
MC was observed in 14/22 evaluable patients (64%). All 14 patients were in CR at that time. Recipient cells accounted for more than 10% of analysed cells in all cases. The rate of MC was 69% (9/13) in patients with uncontrolled disease compared to 56% (5/9) for patients in first or second CR at the time of transplantation. MC was detected at day 28 in 11/14 patients, at day 120 in 1/14 and at day 180 in 2/14 patients. MC affected CD4+, CD8+ and CD19+ cells rather than CD14+ cells (Figures 2 and 3 ).
Early detection of relapse by repeated STR analysis
Recipient cells were detected in all 13 patients who developed a relapse. Impending relapse was indicated by persistent or reappearing MC in 5/13 patients (38%) 4-52 weeks before diagnosis of relapse (8 weeks in median). Four of these five mixed chimeras had no molecular marker of relapse and MC was the only indicator of impending relapse. MC was demonstrated by leucocyte subtype analysis only as whole-blood analysis had indicated CC.
Donor lymphocyte infusions
In total, 28 DLIs were given to 15 patients 61 days in median after NST (range 21-103 days). None of the patients adversely reacted to the thawed cells. Eight patients received no DLI because of unavailability of DLI (n ¼ 1), acute GvHD (n ¼ 2), graft failure (n ¼ 1), early relapsing disease (n ¼ 3) and short follow-up after NST (n ¼ 1).
Nine of 15 patients (60%) developed acute GvHD4grade I after DLI and immunosuppressive therapy with CSA and/or prednisone was instituted in all.
Unstable mixed chimerism
Before DLI, 11/15 patients were mixed chimeras, 3/15 were complete chimeras and in 1/15 chimerism analysis was not performed.
After DLI, 6/11 patients (55%) converted from MC to CC. Recipient cells fell to 5% or less after DLI in 2-6 weeks. A temporary incline of CD8+ recipient cells was seen in one patient after DLI (Figure 2) .
By now, 4/6 patients who converted to CC are alive in CR; one died from relapse 22 months after NST, when GvHD was controlled and one died from sepsis in CR (Table 2 ).
In 5/11 patients, MC persisted despite DLI, although acute GvHD developed in all of them. All five relapsed, 4/5 patients have died from leukaemia and only 1/5 patient is still alive in relapse (Figure 3) .
Three of 14 patients who were mixed chimeras did not receive DLI and all three relapsed, and have died from leukaemia.
Three patients had received DLI in CC. One out of three patients relapsed 6 months later; this patient had received salvage NST after failure of standard SCT (Table 2) .
Discussion
Advanced acute leukaemias might not be good candidates for dose-reduced conditioning because of the rapid kinetics of leukaemic relapse. However, our data show that some patients with high-risk ALL or AML can be cured by NST. Three of 10 surviving patients had uncontrolled disease before NST. Graft failure was rare, although one-third of the patients had an unrelated donor, two-thirds of the patients had uncontrolled disease, and almost all patients received CSA alone as post-transplant immunosuppression. Other groups have reported 20% graft failures after NST. 8, 9 These results have prompted the Seattle group to add fludarabine to sublethal irradiation. 8 The nonmyeloablative preparative regimen used by us 4 was quite intensive as compared to others. 8, 29 We administered 40 mg/kg ATG instead of 10 mg/kg 9 , which suggests that adequate immunosuppression is crucial for donor engraftment. Although the busulfan dose used was also quite high, conditioning therapy was well tolerated by our patients. The high rate of MC observed in our patients and the fact that two patients never had platelets below 20/nl underscores the nonmyeloablative character of the regimen.
It has been shown that dose-reduced conditioning results in a longer time until maximal disease response after transplantation. 5 We hypothesize that conditioning therapy for NST has to be more intensive for patients with acute leukaemias than for those with slowly proliferating diseases such as indolent NHL, MDS or CML, where a more retarded engraftment and remission induction do not endanger the patients.
STR analysis was a valuable tool to assess engraftment and chimerism status after NST. As expected, whole-blood analysis was inferior to leucocyte subpopulations in detecting MC. 10, 11 MC mainly affected lymphocyte subpopulations, while CD14/15+ cells more rapidly showed donor attributes. As a result of the low number of cells very early after transplantation, results might not be unequivocal before haematopoietic reconstitution. Chimerism status in the first weeks after transplantation did not add any relevant information in our study.
Animal studies have demonstrated long-lasting stable MC after low-dose TBI and immunosuppression with CSA and MMF. 12 We have failed to establish stable MC in our patients. All patients with persistent recipient cells have succumbed to leukaemic relapse. Recent clinical data have confirmed that stable MC could not be established in patients after irradiation with 200 cGy alone and relapse ensued, which might hint at immunologic differences between human patients and the canine model. 8 Early detection of relapse after allogeneic SCT in acute leukaemias is hampered by the lack of markers in many patients and the rapid kinetics of disease recurrence. Repeated chimerism analysis of leucocyte subpopulations detected impending relapse before clinical diagnosis in several of our patients without molecular markers.
Although chimerism analysis cannot distinguish prospectively between residual healthy leucocytes of the recipient or incipient leukaemic relapse, our data as well as those from others show that persistent or reappearing recipient cells indicate impending relapse. 11, 14 This methodological limitation of chimerism analysis does not conclusively explain the association of mixed chimerism and relapse; additionally recipient cells of lymphoid lineages were also predictive of later relapse in acute myeloid leukaemia (Figure 3) . Analysis of minimal residual disease will probably allow a deeper insight into the prognostic value of MC. In CML patients, we have observed a relation between bcr-abl detection in bone marrow before cytogenetic or haematologic relapse and MC in peripheral blood (data not shown).
DLI has not cured patients with relapsing ALL and only temporary CR has been restored in single patients, the results in relapsing AML being only slightly better. 16, 18 Therefore, a beneficial role of DLI in relapsing AML and even less in ALL has not been demonstrated so far.
Only early intervention before clinical relapse can improve the prognosis of these patients. 19 We treated our patients with prophylactic DLI, because of the anticipated high relapse risk of advanced acute leukaemias after SCT. 30 A GvL-effect of DLI in these patients can be concluded from the fact that all but one patient with late relapse, who converted from MC to CC, had continuous remission, whereas all patients who remained mixed chimeras relapsed (Table 2) . A GvL-effect in ALL has also been demonstrated in two patients with Ph+ALL with persistent bcr-abl transcript, who reached complete molecular remission after either termination of immunosuppression or DLI. 31 DLI was followed by a high rate of severe GvHD, although transplant-related mortality was low in our study, which underlines that toxicity of the conditioning regimen is acceptable. The GvL-effect of DLI did not parallel GvHD, because 2/6 converting patients did not develop GvHD and five patients with persistent MC developed GvHD. Other authors have also reported a high rate of acute and chronic GvHD after prophylactic DLI. [32] [33] [34] [35] A higher transplant-related mortality was reported in these studies after dose-reduced 32, 33 as well as after standard high-dose conditioning. 34, 35 The optimal time point and cell dose of DLI have not been established. In our opinion, chimerism analysis of leucocyte subsets should be started early after engraftment in the first month after NST and repeated monthly for the first 6 months at least in high-risk patients. We have continued to start DLI after day +60.
In conclusion, a substantial proportion of patients with high-risk acute leukaemias can be cured by NST and prophylactic DLI, if complete donor chimerism can be achieved and maintained. Chimerism analysis of leucocyte subsets detected impending relapse early. MC is not stable in these patients and results in relapse of the disease.
The administration of prophylactic DLI can convert MC to CC in patients with high-risk ALL and AML and seems to lower relapse risk.
The number of patients analysed is quite small and only investigation of a larger number of patients and close surveillance of chimerism status compared with cytogenetic and molecular markers of minimal residual disease can clarify the value of MC, and allow an individually adjusted administration of prophylactic DLI.
